PSME4 Antibody - BSA Free

Western Blot: PSME4 Antibody [NBP2-22236] - Whole cell lysate from 293T (15 and 50 ug), HeLa (50 ug), and Jurkat (50 ug) cells. NBP2-22236 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.

Immunohistochemistry-Paraffin: PSME4 Antibody [NBP2-22236] - Human non-small cell lung cancer. Antibody: Affinity purified rabbit anti- PSME4 used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: Hematoxylin (blue).

Immunoprecipitation: PSME4 Antibody [NBP2-22236] - Whole cell lysate (1 mg for IP; 20% of IP loaded) from 293T cells. NBP2-22236 used for IP at 6 ug/mg lysate. PSME4 was also immunoprecipitated by rabbit anti-PSME4 antibody. For blotting immunoprecipitated PSME4, NBP2-22236 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.

• Reactivity: Hu
• Applications: WB, IHC, IP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

PSME4 Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit PSME4 Antibody - BSA Free (NBP2-22236) is a polyclonal antibody validated for use in IHC, WB, ICC/IF and IP. Anti-PSME4 Antibody: Cited in 7 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: The immunogen this antibody was made to, maps to a region between residue 1 and 50 of human Proteasome (Prosome, Macropain) Activator subunit 4 using the numbering given in entry NP_055429.2 (GeneID 23198).
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: PSME4
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1:500- 1:2000
  • Immunoprecipitation 2 - 10 ug/mg
  • Western Blot 1:1000 - 1:5000
• Application Notes: Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections.

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Tris-Citrate/Phosphate (pH 7.0 - 8.0)
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for PSME4 Antibody - BSA Free

• proteasome (prosome, macropain) activator subunit 4

Background

Proteolytic degradation is critical to the maintenance of appropriate levels of short-lived and regulatory proteins as important and diverse as those involved in cellular metabolism, heat shock and stress response, antigen presentation, modulation of cell surface receptors and ion channels, cell cycle regulation, transcription, and signalling factors. The ubiquitin-proteasome pathway deconstructs most proteins in the eukaryotic cell cytosol and nucleus. Other proteins are degraded via the vacuolar pathway which includes endosomes, lysosomes, and the endoplasmic reticulum. The 26S proteasome is an ATP-dependent, multisubunit (~31), barrel-shaped molecular machine with an apparent molecular weight of ~2.5 MDa. It consists of a 20S proteolytic core complex which is crowned at one or both ends by 19S regulatory subunit complexes. The 19S regulatory subunits recognize ubiquitinated proteins and play an essential role in unfolding and translocating targets into the lumen of the 20S subunit. The PA28/11S REG Activator protein complex functions as a proteolytic activator. PA200 has been identified as a 200 kDa nuclear protein that activates the 26S proteasome complex. Studies have shown that, in human tissues, PA200 mRNA levels are highest in testis, but is also present in liver, spleen, brain, heart, kidney and lung. Evidence suggests that this protein is involved in DNA repair, possibly by recruiting the proteasome to double-strand DNA breaks.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for PSME4 Antibody (NBP2-22236)(7)

Publications using NBP2-22236

• Mamrosh JL, Sherman DJ, Cohen JR et al. Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation Science advances 2023-06-23 [PMID: 37352349] (WB, Human)
• Yazgili AS, Ebstein F, Meiners S The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease Biomolecules 2022-08-20 [PMID: 36009043] (WB, Human)
• Yazgili AS, Meul T, Welk V et al. In-gel proteasome assay to determine the activity, amount, and composition of proteasome complexes from mammalian cells or tissues STAR protocols 2021-06-18 [PMID: 34027484]
• Aladdin, A, Yao, Y Et al. The Proteasome Activators Blm10/PA200 Enhance the Proteasomal Degradation of N-Terminal Huntingtin. Biomolecules 2020-11-20 [PMID: 33233776] (WB, ICC/IF, Human)
• de Jesus AA, Brehm A, VanTries R et al. Novel Proteasome Assembly Chaperone mutations in PSMG2/PAC2, cause the autoinflammatory interferonopathy, CANDLE/PRAAS4. J. Allergy Clin. Immunol. 2019-01-18 [PMID: 30664889] (WB, Human)
• Zieba, B A, Henry, L Et al. The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin. J Dermatol Sci 2017-10-01 [PMID: 28728908] (ICC/IF, Human)
• Welk V, Coux O, Kleene V et al. Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes. J. Biol. Chem. 2016-04-18 [PMID: 27129254] (WB, Human)

Bioinformatics

• Gene Symbol: PSME4
• Uniprot:
  • NP_055429.2(Human)